United Therapeutics Inc., of Silver Spring, Md., reported net revenues of $445.5 million for the third quarter. Sales of pulmonary arterial hypertension drugs Remodulin (treprostinil injectable), Tyvaso (treprostinil inhaled), Orenitram (treprostinil extended-release tablets) and Unituxin (dinutuximab) reached $187.3 million, $88.9 million, $52.5 million and $17 million, respectively. United reported net income of $276.3, and non-GAAP net earnings of $206.9 million, or $4.69 per diluted share, beating analyst estimates of $3.87 per share. The company ended the quarter with total cash and equivalents of about $1.6 billion. Shares of United (NASDAQ:UTHR) rose $4.24, to close Wednesday at $123.14.